Where Weight-Loss Clinics Cross the FDA's Line on Compounded GLP-1

If you run a GLP-1 or medical weight-loss clinic, three marketing patterns draw far more FDA and FTC attention than anything else: promoting compounded semaglutide or tirzepatide without saying it is compounded and not FDA-approved, claiming your product is the “same as” Ozempic, Wegovy, or Mounjaro, and sourcing from facilities the FDA has flagged for quality or approval problems. None of these require bad intent. A page copies a supplier’s language, a landing page reaches for a familiar brand name, and your service copy now makes a claim the practice cannot back up. This post walks through what trips each pattern, the real enforcement that shows the pattern in action, and the safer way to say the same thing.

TL;DR

• Compounded is not FDA-approved, and your copy has to say so. Marketing compounded semaglutide or tirzepatide as if it were the branded, approved drug is the single most common trigger. Compounded drugs are not FDA-approved and do not carry the same review [5].
• “Same as Ozempic” needs data you do not have. Brand-equivalence claims imply bioequivalence. Unless you hold the studies that prove it, the FTC treats that as an unsubstantiated comparison [1][4].
• Your supplier is part of your risk. Sourcing from manufacturers or outsourcing facilities the FDA has cited pulls your clinic into the same enforcement story. Recent actions hit New Life Pharma, ProRx, and Boothwyn Pharmacy [3].
• The FDA angle is “unapproved drug,” the FTC angle is “deceptive.” A single sentence can draw both. The FDC Act defines what makes a product a “drug,” and the FTC Act polices whether the claim is substantiated [2][4].
• A scan is not a clearance. Our free Claim Checker flags these patterns, but your clinic’s own physician and your counsel remain the final gate on any medical claim.

Trigger one: marketing compounded GLP-1 as if it were approved

This is the pattern that drives most of the GLP-1 enforcement clinics see. Compounded semaglutide and tirzepatide are not FDA-approved products. Compounding produces a drug for a specific patient need, but it does not go through the FDA review that branded Ozempic, Wegovy, Zepbound, and Mounjaro went through, and the agency does not verify a compounded drug’s safety, effectiveness, or quality the same way [5].

What trips the FDA is copy that erases that distinction. A weight-loss page that advertises “semaglutide” or “tirzepatide” with no disclosure reads, to a regulator and to a patient, as the approved drug. The Lovega LLC action (operating as Pink Pony Peptides) centered on a website marketing GLP products including tirzepatide, which is exactly the marketing-surface problem clinics need to watch, not just a manufacturing problem (Atlas entry).

The safer phrasing. Name the product honestly and disclose its status in the same breath. Instead of “Get semaglutide at our clinic,” something closer to “We offer compounded semaglutide, which is prepared by a licensed pharmacy and is not FDA-approved.” Do not imply the compounded version carries branded-drug review. Let the patient see the distinction your supplier and your physician already know about.

Trigger two: “same as Ozempic” brand-equivalence claims

The second pattern is the equivalence claim. “Our semaglutide is the same as Wegovy.” “Identical to Mounjaro at a fraction of the price.” These read as marketing shorthand, but a “same as” claim is a scientific assertion. It implies bioequivalence, meaning the product delivers the same active ingredient at the same rate and extent as the reference drug. Proving that takes bioequivalence data, and clinics offering compounded products do not hold those studies.

That is an FTC problem before it is an FDA problem. The FTC requires “competent and reliable scientific evidence” behind objective health claims, and a head-to-head equivalence claim is about as objective as it gets [1]. Under Section 5 of the FTC Act, a comparison you cannot substantiate is a deceptive act [4]. The brand names also carry trademark exposure, but the substantiation gap is what makes it an enforcement issue.

The safer phrasing. Describe your actual product without leaning on a brand to do the selling. Instead of “same as Ozempic,” you can say “compounded semaglutide uses the same active ingredient, semaglutide,” which is a factual ingredient statement, not an equivalence claim, and avoid “same as,” “identical to,” “just like,” and “generic version of” a named brand. If a patient asks how it compares, that is a clinical conversation for your physician, not a headline.

Trigger three: sourcing from flagged manufacturers and facilities

The third pattern is upstream of your copy but lands on your clinic anyway: where the product comes from. The FDA has been active against the manufacturers and outsourcing facilities feeding the GLP-1 market, and a clinic that sources from a cited facility inherits the exposure.

The recent record is specific. New Life Pharma LLC was cited for manufacturing and distributing unapproved semaglutide and tirzepatide sterile vials (Atlas entry). ProRx LLC, a 503B outsourcing facility, was cited for compounding tirzepatide and semaglutide under insanitary conditions. Boothwyn Pharmacy LLC was cited in January 2026 for sterile-compounding deficiencies while distributing GLP-1 injectables. These are FDA Warning Letter and enforcement actions, the public record clinics can check before they sign a supply agreement [3].

The safer practice. This one is less about phrasing and more about diligence. Know whether your compounding pharmacy is a 503A or 503B facility, ask about its inspection history, and do not market product whose origin you cannot stand behind. If your copy says “pharmacy-grade” or “made in a certified facility,” your physician should be able to point to the documentation that makes that true. The full GLP-1 enforcement record lives in the GLP-1 Atlas category.

How to check your GLP-1 copy

You do not need to memorize the Food, Drug, and Cosmetic Act to catch the obvious risks. Most GLP-1 copy problems are a short, repeating list: an undisclosed “compounded,” a stray brand name, an equivalence verb, an absolute-safety phrase.

Our free Claim Checker scans pasted copy against the same FDA and FTC patterns described here and shows the regulator precedent next to each flag. Nothing leaves your browser. Run your weight-loss landing pages, intake emails, and ad copy through it before they go live. For the broader pattern across every clinic vertical, the pillar guide on the marketing claims that trigger FDA Warning Letters covers cure claims, safety claims, and substantiation in detail.

A scan is a screen, not a sign-off. It catches the known patterns. It does not replace your clinic’s own licensed physician or your counsel, the final gate on any medical claim you publish.

Frequently asked questions

Can I advertise that my clinic offers semaglutide or tirzepatide?

Yes, but how you say it matters. If you are dispensing compounded product, your copy should make clear that it is compounded and not FDA-approved, rather than presenting it as the branded, approved drug [5]. The honest version of the claim is usually the safer version: name the product, name its status, and let your physician handle the clinical comparison with the patient.

Why can’t I say my product is the “same as” Ozempic or Wegovy if it has the same active ingredient?

Because “same as” is an equivalence claim, and equivalence implies bioequivalence, which requires data showing the product behaves the same way in the body as the reference drug. Clinics offering compounded products generally do not hold those studies, so the FTC treats the comparison as unsubstantiated under its evidence standard and Section 5 [1][4]. You can factually state that a product contains the same active ingredient without claiming the products are interchangeable.

Does the FDA’s enforcement only target manufacturers, or can it reach my clinic’s marketing?

Both. The manufacturer and outsourcing-facility actions, like New Life Pharma and ProRx, focus on production and distribution, but marketing-surface cases like Lovega (Pink Pony Peptides) show the FDA also looks at how GLP products are marketed on a website [3]. A clinic’s own service pages and ads are part of the picture, which is why the language you publish carries real exposure.

Is running my copy through a Claim Checker enough to be compliant?

No. The Claim Checker is a screening tool that flags known FDA and FTC patterns so you can fix them before publishing. It is educational, not a compliance clearance. Your clinic’s own physician and your legal counsel are the final reviewers of any medical claim, and they should sign off before copy goes live.

Citations

1. Federal Trade Commission. Health Products Compliance Guidance. December 2022. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance . Accessed June 8, 2026.
2. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act, Section 201(g) (definition of “drug”). https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act . Accessed June 8, 2026.
3. U.S. Food and Drug Administration. Warning Letters. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters . Accessed June 8, 2026.
4. Federal Trade Commission. Enforcement Authority (Section 5, deceptive or unfair acts). https://www.ftc.gov/about-ftc/mission/enforcement-authority . Accessed June 8, 2026.
5. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers . Accessed June 8, 2026.